课题基金 / 基金详情

MULTICENTER PHASE III BLINDED STUDY OF DAB389IL-2 IN CTCL > 4 PREVIOUS THERAPIES

MULTICENTER PHASE III BLINDED STUDY OF DAB389IL-2 IN CTCL > 4 PREVIOUS THERAPIES
DAB389IL-2 在 CTCL 中的多中心 III 期盲研究 > 4 种既往疗法
批准号：
6114554
负责人：
BRIAN JEGASOTHY
金额：
$2.9万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/6114554
关键词：
clinical research human subject human therapy evaluation immunoconjugates interleukin 2 mycosis fungoides lymphoma neoplasm /cancer immunotherapy

项目摘要

项目成果

BRIAN JEGASOTHY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This Phase III study is designed to evaluate the efficacy and safety of an IL-2 receptor (IL-2R) targeted cytotoxin DAB389IL-2 as second line therapy in patient with cutaneous T-cell lymphoma (CTCL) who, following >4 previous therapies or stage IVa disease patients following >1 previous therapy, have recurrent or persistent disease. Cutaneous T-cell lymphoma is a heterogeneous group of malignancies of the T-helper/inducer lymphocyte subset. In 50% of cases, these malignant cells express IL-2R as demonstrated by immunohistochemical staining.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
PHASE I STUDY OF BMS-188667 IN PATIENTS WITH PSORIASIS VULGARIS
MULTICENTER PHASE 3 TRIAL OF DAB3891L-2 IN CTCL PATIENTS IN STAGE IA-IVA DISEASE
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
海外基金